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Nonalcoholic fatty liver disease (NAFLD) has been considered a novel component of the metabolic syndrome (MetS), with the
oxidative stress participating in its progression. This study aimed to evaluate the metabolic profile in young and old mice with
MetS, and the effects of apocynin and tempol on glycemic and lipid parameters. Young and old C57BL/6 mice with high fat diet-
(HFD-) induced MetS received apocynin and tempol 50mg⋅kg−1/day in their drinking water for 10 weeks. After HFD, the young
group showed elevated fasting glucose, worsened lipid profile in plasma, steatosis, and hepatic lipid peroxidation. Nevertheless,
the old group presented significant increase in fasting insulin levels, insulin resistance, plasma and hepatic lipid peroxidation,
and pronounced steatosis. The hepatic superoxide dismutase and catalase activity did not differ between the groups. Tempol and
apocynin seemed to prevent hepatic lipid deposition in both groups. Furthermore, apocynin improved glucose tolerance and
insulin sensitivity in old mice. In summary, old mice are more susceptible to HFD-induced metabolic changes than their young
counterparts. Also, the antioxidant therapy improved insulin sensitivity and glucose tolerance, and in addition, apocynin seemed
to prevent the HFD-induced hepatic fat deposition, suggesting an important role of oxidative stress in the induction of NAFLD.
1. Introduction
Nonalcoholic fatty liver disease (NAFLD), characterized by
fatty infiltration of the liver, has been considered a novel
component of the metabolic syndrome (MetS) [1–4], the
latter being a multifactorial condition that gathers various
cardiovascular risk factors and metabolic disorders [2, 3].
NAFLD encompasses various degrees of liver damage,
ranging from simple steatosis to a complex and more
dangerous presentation, steatohepatitis [5], and it is often
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accompanied by oxidative stress [6], a condition of imbalance
in the prooxidant/antioxidant balance in favor of prooxidants
[7].
The liver is a central organ for the maintenance of
systemic lipid and glucose homeostasis and, due to this fact,
it is susceptible to oxidative stress damage [8, 9]. The latter
plays a critical role in the progression of metabolic disorders,
including insulin resistance, one of the conditions which
characterize theNAFLD [4]. In addition, oxidative stressmay
induce several pathophysiological events in the liver, such as
detrimental effects on hepatocytes by damaging DNA, lipids,
and proteins, ultimately leading to disruptions in cellular
homeostasis [2, 10].
Nicotinamide adenine dinucleotide phosphate oxidase
(NAD(P)H oxidase) is an enzyme involved in the progression
of the disorders related to the MetS, such as liver injury [11],
hyperglycemia [12], increased oxidative stress in diabetes and
obesity [2, 13], hypertension [14], and impaired endothelium-
dependent dilation [15]. Also, that enzyme appears to play
an essential role in a higher insulin-stimulated hydrogen
peroxide (H
2
O
2
) generation in skeletal muscle [16].
Although NAD(P)H oxidase is the major source of reac-
tive oxygen species (ROS) production [13, 17], the antioxidant
enzymes superoxide dismutase (SOD), catalase (CAT), and
glutathione peroxidase (GPx) have a critical importance in
the metabolism of ROS [7]. SOD is responsible for dismuting
the superoxide anion (∙O
2
−
) into H
2
O
2
, which, in turn, is
removed by CAT and GPx, finally being converted into water
andO
2
[7]. In this scenario, these enzymes exert an important
protective function against ROS,which are increasedwith age
[18, 19] and in high fat diet- (HFD-) induced obesity, as well
as in MetS and NAFLD animal models [1, 4, 9, 20].
Even though several studies have been conducted to
assess the metabolic effects of the consumption of HFD in
animal models [16, 21, 22], little is known about its effect con-
comitant with antioxidant therapy in old age and in theMetS.
Based upon this scenario, we hypothesized that aged mice
are more sensitive to HFD-induced metabolic changes than
younger mice and that the concomitant antioxidant therapy
is effective in reducing the negative metabolic impacts from
HFD consumption. In order to test this hypothesis, we
assessed the metabolic profile in young and old C57BL6
mice presenting with MetS and sought to investigate the
preventive effects of apocynin, a NAD(P)H oxidase inhibitor,
and tempol, a SOD mimetic, on HFD-induced metabolic
changes in those animals.
2. Materials and Methods
2.1. Animals and Experimental Procedures. C57BL/6 male
young and old mice used in this study were purchased from
Federal University of Alagoas at 6–8 weeks and 54–56 weeks
of age, respectively. During all the experimental period, mice
were kept on a 12-hour light/dark cycle and fed and hydrated
ad libitum, with controlled humidity and temperature. All
procedures were carried out in accordance with the criteria
outlined in the Guide for the Care and Use of Laboratory
Animals (NIH publication 86-23, 1996) and approved by the
Institutional Ethics Committee of the Federal University of
Alagoas (Protocol 005208/2010-46).
Young (Y) and old (O) mice were divided into two
groups and fed different diets during 14 weeks: high fat
diet, which was developed by our group, with the other
nutrient contents in accordance with the American Institute
of Nutrition’s recommendation (AIN-93) [23, 24] (HF-Y and
HF-O) (58.4% kcal lipids from lard; 26.6% kcal carbohy-
drates, i.e., sucrose; 15% kcal protein, i.e., casein) or standard
chow diet (CT-Y and CT-O) (11.8% kcal lipids, 62.6% kcal
carbohydrates, and 25.6% kcal protein). After 4weeks ofHFD
(the required period for the glycemic alterations to appear,
a time interval previously detected in other experimental
groups conducted by our laboratory, with blood glucose
levels assessed weekly—Accu-Chek Performa, Roche®, Sa˜o
Paulo, Brazil), the HF-Y and HF-O groups were divided into
three subgroups according to their treatment: (1) positive
control that continued receiving only HFD and normal
water (HF-Y and HF-O); (2) HFD plus oral treatment with
tempol (50mg⋅kg−1/day, dissolved in drinking water) (HFT-
Y and HFT-O); (3) HFD plus oral treatment with apocynin
(50mg⋅kg−1/day, dissolved in drinking water) (HFA-Y and
HFA-O). The exact duration of the tempol and apocynin
interventions was 10 weeks. The dosages of tempol and
apocynin were recalculated weekly, taking into account the
mean body weight recorded every week and the liquid
consumption of the groups.
2.2. Intraperitoneal Glucose Tolerance Test (GTT) and Insulin
Tolerance Test (ITT). At the end of treatment, fasting blood
glucose was assessed (12 h fast) using a glucometer (Accu-
Chek Performa, Roche, Sa˜o Paulo, Brazil). Next, 2 g glu-
cose/kg of body weight was intraperitoneally injected and
blood from the tail vein was collected again at 15, 30, 60,
90, and 120 minutes for measuring glucose levels. Two days
later, baseline blood glucose was measured in fed state.
Sequentially, insulin (0.75 units/kg of bodyweight;Humulin®,
Eli Lilly, Indianapolis, IN) was intraperitoneally administered
and tail blood samples were obtained at 15, 30, and 60minutes
to obtain blood glucose levels.
2.3. Euthanasia and Organ Collection. After intraperitoneal a
nesthesia using a xylazine/ketamine solution (10/110mg⋅kg−1),
the cephalocaudal length and abdominal circumference were
measured (cm) and the animals were sacrificed by exsan-
guination through cardiac puncture of the right ventri-
cle. Blood was collected and centrifuged and plasma was
separated and stored at −80∘C until biochemical analyses
were performed. Liver, adipose tissues, heart, gastrocnemius
muscle, and intestine were carefully perfused, removed, and
weighed. Next, one piece of the right hepatic lobe was
selected for histological analysis, and two more pieces (∼
100mg) were immediately snap-frozen in dry ice and stored
at −80∘C for assessing lipid profile and the activities of
antioxidant enzymes. Similarly, adipose tissues (epididymal,
perirenal, and mesenteric) were stored at −80∘C for further
analysis. White adipose tissue (WAT) index was calculated
following the formula: WAT index (%) = [(epididymal fat
(g) + perirenal fat (g))/(body weight (g)) ∗ 100] [25]. The
Oxidative Medicine and Cellular Longevity 3
relative weight (%) of adipose tissue was calculated as follows:
relative weight (%) = [(adipose tissue (g)/body weight (g))
∗ 100]. Liver, gastrocnemius, heart, and intestine mass were
normalized by tibial length and expressed as g/mm of tibial
length. Finally, right tibias were also removed and had their
lengths measured.
2.4. Plasma Lipid Analysis. Total cholesterol, triglyceride,
and free fatty acids (FFA) levels in plasma were assayed using
commercial kits (enzymatic colorimetric assay; Labtest®,
Lagoa Santa, Brazil, and Wako Chemicals GmbH®, Neuss,
Germany), following the manufacturer’s instructions with
adaptations for microplate (Thermo Scientific®, Software 2.4
Multiskan Spectrum, Vantaa, Finland). VLDL was calculated
as follows: VLDL = triglyceride/5 [26].
2.5. Insulin Measurement and Markers of Insulin Resistance.
Insulin levels were quantified using an ELISA assay (Mil-
lipore®, Schwalbach, Germany) according to the manufac-
turer’s instructions. The product of fasting triglycerides and
glucose (TyG index) was calculated following the formula:
TyG index = Ln [fasting triglyceride (mg⋅dL−1) × fasting
glucose (mg⋅dL−1)/2] [27, 28].The homeostasis model assess-
ment (HOMA index) was calculated as follows: HOMA index
= [fasting glucose (mg⋅dL−1) × fasting insulin (𝜇U⋅mL−1)/
405] [29].
2.6. Evaluation of Liver Injury. Commercial kits (Labtest,
Lagoa Santa, Brazil) adapted for microplate reading (Thermo
Scientific, Software 2.4Multiskan Spectrum,Vantaa, Finland)
were used for evaluating in plasma the degree of liver injury
and function by measuring the enzymatic concentrations of
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), alkaline phosphatase (ALP), 𝛾-glutamyltransferase
(𝛾-GT), and lactate dehydrogenase (LDH). Levels of total
protein [30] and albumin were also determined.
2.7. Liver Histological Analysis. In order to investigate liver
structure and the occurrence of steatosis, small hepatic frag-
ments were fixed in 10%buffered formaldehyde, embedded in
paraffin, sectioned at 4–6 𝜇m, and stained with hematoxylin
and eosin (H&E). The sections from each animal were his-
tologically examined in light microscope (Olympus®, Tokyo,
Japan) and photographed (Kodak digital camera, Eastman
Kodak Company, Rochester, NY, USA).
2.8. Liver Lipids Analysis. Total hepatic lipids were extracted
from liver samples according to a gravimetric standard
method [31], followed by measurement of cholesterol and
triglyceride levels using commercial kits (enzymatic colori-
metric assays; Labtest, Lagoa Santa, Brazil) according to the
manufacturer’s instructions, with adaptations for microplate
(Thermo Scientific, Software 2.4 Multiskan Spectrum, Van-
taa, Finland), and VLDL as described [26].
2.9. Protein Extraction fromLiver Samples. Fromeachmouse,
a piece of frozen liver was homogenized in a RIPA lysis buffer
(Cell Signaling®, Beverly, MA, USA) plus protease and phos-
phatase inhibitor cocktails (Roche, Mannheim, Germany).
Following the extraction, total protein concentration was
quantified by the Bradfordmethod [30] and the samples were
stored at −80∘C for subsequent measurements.
2.10. Measurement of Lipid Peroxidation. Thiobarbituric acid
reactive substances(TBARS),mainlymalondialdehyde (MDA),
are widely used as a marker of lipid peroxidation. Such
quantification was performed according to Ohkawa et al. [32]
with some adaptations. Briefly, 100 𝜇L of hepatic homogenate
samples or 100 𝜇L of plasma was individually mixed with
10 𝜇L of butylated hydroxytoluene (final concentration =
1mmol⋅L−1) and 1250 𝜇L of thiobarbituric acid (1.3%; Sigma
Aldrich®, Seelze, Germany). Then, samples were heated at
100∘C during 60 minutes, being next incubated in ice bath (∼
4∘C) for 10minutes to stop the reaction. Sequentially, samples
were centrifuged at 1600 g per 15 minutes at 4∘C. In order
to remove the interfering absorbance, for each sample, the
value of the absorbance at 600 nm was subtracted from the
value read at 532 nm. Finally, values were normalized for total
protein concentration and expressed as nM⋅mg protein−1
[30].
2.11. Superoxide Dismutase (SOD) and Catalase (CAT) Activi-
ties. Total SOD activity was assessed in 20 𝜇L of liver homo-
genate with a commercial colorimetric kit (Sigma Aldrich,
Seelze, Germany) following the manufacturer’s instructions
and read in a microplate reader (Thermo Scientific, Software
2.4 Multiskan Spectrum, Vantaa, Finland) at 450 nm. The
obtained values were normalized by total protein concentra-
tion in the liver [30] and expressed as IU⋅protein−1, mg of
hepatic protein. Catalase activity was measured according to
Xu et al. [33], being expressed as 𝜇mol/min/mL⋅protein−1, mg
[30].
2.12. Statistical Analysis. The data are expressed as mean ±
standard error of the mean (SEM), and 𝑝 < 0.05 was consid-
ered statistically significant. Analyses were performed using
the one- or two-way ANOVA, when applicable (followed by
Bonferroni’s post hoc test) (Graph pad Prism® 5.0, San Diego,
CA, USA).
3. Results
3.1. General Parameters, Fat Deposition, and Lipid Profile in
Mice with MetS and Treated with Antioxidant Therapy. The
measurements of food intake, animal growth, abdominal
circumference, and lipids and glucose metabolism, variables
which can be changed during the consumption of a HFD,
were done to evaluate the possible effects of HFD and of the
antioxidant treatment with apocynin and tempol in mice at
different ages.
The data showed that the food intake, regardless of age,
was statistically lower in HFD-fed groups (HF-Y and HF-
O; Table 1). However, the energy consumed did not differ
between groups, since the HFD displays a caloric content
greater than the chow diet, thus normalizing the caloric
intake (data not shown). Besides, abdominal circumference
was increased in HF-O compared to CT, without differences
between the young groups. With respect to the influence of
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Figure 1: Body weight andWAT index. Monitoring of body weight (g) during the weeks before and after pharmacological intervention with
tempol (50mg⋅kg−1) and apocynin (50mg⋅kg−1) in young (a) and old (c) C57BL/6 mice. WAT index (%) and representative pictures of the
HF diet animals after pharmacological intervention in young (b) and old (d) C57BL/6 mice. CT = control group; HF = high fat diet group;
HFT = high fat diet + tempol group; HFA = high fat diet + apocynin group. Each point of the graph represents the mean ± SEM. ANOVA
(two-way) with Bonferroni’s post hoc test: ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001, CT versus HF. Each bar graph represents the mean ± SEM.
ANOVA (one-way) with Bonferroni’s post hoc test: ∗∗∗𝑝 < 0.001, CT versus HF (𝑛 = 5-6).
HFDon animal growth, no statistical differencewas observed
in tibial and cephalocaudal length between young and old
groups. Neither tempol nor apocynin had effect on any of
these aforementioned parameters during HFD intake in both
groups (Table 1).
Although no significant difference in body weight was
observed between the young groups during the HFD con-
sumption (Figure 1(a)), the WAT index (Figure 1(b)) and
relative epididymal, perirenal, and mesenteric fat weight
(Table 1) were significantly higher. However, in one of the old
groups (HF-O), a significant increase was observed in body
weight compared with CT-O from the 8th week (𝑝 < 0.05)
until the end of treatment (𝑝 < 0.001) (Figure 1(c)), indi-
cating that aging enhances the metabolic effects associated
with HFD consumption. The WAT index (Figure 1(d)) and
the relative epididymal, perirenal, and mesenteric fat weight
(Table 1) were also significantly higher in old animals after
HFD consumption. In both young and old groups, apocynin
and tempol had no effects on body weight, WAT index,
and relative adipose tissue weight during HFD intake when
compared to the respective control (HF-Y and HF-O, resp.).
TheHFDdid not change skeletalmusclemass (gastrocne-
mius mass) in young and old groups (Table 1). On the other
hand, the intestinal mass was significantly decreased in both
young and old groups that received HFD. In addition, the
heart mass was significantly lower in the HF-Y but not in
HF-O (Table 1), suggesting that induction of muscle loss by
consumption of HFD is more pronounced in the younger
compared to older age. HF-Y mice, although not presenting
an increase in body weight, showed a markedly elevated
concentration of total cholesterol, triglycerides, VLDL, and
FFA in plasma compared with CT-Y (Figures 2(a), 2(c), 2(e),
and 2(g), resp.). Similarly, HF-O mice presented elevated
total cholesterol, triglycerides, and VLDL levels but not FFA
compared to the CT-O (Figures 2(b), 2(d), 2(f), and 2(h),
resp.). Lipid peroxidation was not different between the
young groups, but the old HFD group presented significant
increase in this parameter, which was decreased after apoc-
ynin treatment (Figures 2(i) and 2(j)). In the old group, both
tempol and apocynin were also able to decrease the levels of
triglycerides and VLDL in plasma (Figures 2(d) and 2(f)).
3.2. Glycemic Profile in Mice with MetS and Treated with
Antioxidant Therapy. As shown in Figure 3, the basal levels
of glucose (Time 0) in young and old mice were not different.
However, after receiving HFD during 4 weeks (Time 1),
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Figure 2: Continued.
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Figure 2: Lipid profile in plasma. Total cholesterol in plasma (mg⋅mL−1) in young (a) and old (b) C57BL/6 mice. Triglycerides in plasma
(mg⋅mL−1) in young (c) and old (d) C57BL/6 mice. Very-low-density lipoprotein (VLDL) in plasma (mg⋅mL−1) in young (e) and old (f)
C57BL/6 mice. Free fatty acids (FFA) in plasma (mmol⋅L−1) in young (g) and old (h) C57BL/6 mice. Lipid peroxidation in plasma ([TBARS]
nM⋅mg protein−1) in young (i) and old (j) C57BL/6 mice. CT = control group; HF = high fat diet group; HFT = high fat diet + tempol
group; HFA = high fat diet + apocynin group. Each bar graph represents the mean ± SEM. ANOVA (one-way) with Bonferroni’s post hoc test:
∗
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< 0.05; ∗∗𝑝 < 0.01, CT versus HF; 𝛿𝑝 < 0.05, HFT versus HF; ##𝑝 < 0.01, HFA versus HF (𝑛 = 5-6).
these groups (HF-Y andHF-O) presented significantly higher
fasting glucose compared to their respective CT groups (CT-
Y and CT-O). At this point, we started the pharmacological
intervention with tempol and apocynin during 10 weeks. At
the end of treatment (Time 2), regardless of age, no statistical
difference in glucose concentration was observed for tempol
groups (HFT-Y, HFT-O) compared to their respective HFD
groups (HF-Y and HF-O). Nevertheless, apocynin signifi-
cantly decreased the final fasting glucose in old animals with
MetS, but not in the young ones (Figures 3(a) and 3(b)).
HF-Y and HF-O mice presented increased glucose intol-
erance (Figures 3(c) and 3(d)). This effect was evident by the
higher time-dependent glucose concentration at 15, 30, 60,
and 90min after the intraperitoneal injection of glucose, as
well as by the significant increase in the AUC in the HF-
Y and HF-O groups compared with the correspondent CT
group. Apocynin, a NAD(P)H oxidase inhibitor, seems to
prevent the occurrence of such effects in both young and old
mice with MetS. On the other hand, tempol, a SODmimetic,
was shown to be capable of reducing the occurrence of the
aforementioned changes only in old mice.
Interestingly, the young mice (HF-Y) did not show
decreased insulin sensitivity after HFD consumption, a fact
observed in old mice (HF-O) during the ITT, and when
calculating the AUC from these data (Figures 3(e) and 3(f)).
Time-dependent glucose concentration in ITT and the AUC
decreased in the HFT-O and HFA-O compared with the HF-
O group, indicating that both apocynin and tempol improved
insulin sensitivity in old mice. In addition, we measured the
fasting insulin concentrations in plasma, with no differences
observed in young groups after HFD, but with a significant
increase in the old group. Additionally, in the treated groups,
neither tempol nor apocynin had effects on that parameter in
the old group. However, in the young group, both treatments
decreased the insulin levels compared to the HFD group
(Table 2). Analysis of the insulin resistance markers, TyG
index and HOMA index, showed that only in old animals
these parameters were increased after HFD consumption,
with both treatments, tempol and apocynin, being able to
significantly decrease the TyG index in old animals (Table 2).
3.3. Function, Lipid Profile, and Redox State in Liver Samples
of Mice with MetS and Treated with Antioxidant Therapy. In
order to evaluate the effect of the improved glycemic profile
on liver metabolism after pharmacological intervention, we
assessed markers of liver injury and function, fat accumula-
tion, and hepatic redox balance.
The liver weight in young mice that consumed HFD was
significantly lower compared to that observed in animals fed
standard chow diet (Figure 4(a)). On the other hand, the HF-
O showed a significant increase in liver weight (Figure 4(b)).
The analysis of plasma markers of hepatocellular injury
(ALT, AST, and LDH), canalicular enzymes (ALP, 𝛾-GT),
and markers of liver function (albumin and total proteins) is
shown in Table 2. In both young and old mice, AST and ALT
levels were increased in HF group compared to CT group,
indicating the elevated hepatic injury in these animals after
the HFD consumption.The treatment with tempol decreased
the levels of AST and ALT in plasma of young animals, but
not in the old ones. Additionally, the other hepatic markers
evaluated were not found to be different between the groups.
The quantification of total lipids and fractions (total
cholesterol, triglycerides, and VLDL) showed an increase
after HFD consumption in both young and old animals
(Figures 4(c)–4(j)). No significant changes were observed in
the concentration of all the parameters listed above in groups
treated with tempol. However, apocynin treatment was able
to decrease the levels of triglycerides and VLDL in liver of
young animals with MetS (Figures 4(e) and 4(f)).
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Figure 3: Glycemic profile. Fasting glucose (mg⋅dL−1) at three different points (basal fasting glucose: Time 0; beginning of pharmacological
intervention with tempol (50mg⋅kg−1) and apocynin (50mg⋅kg−1): Time 1; and the end of pharmacological intervention: Time 2) and end
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Each point of the graph represents the mean ± SEM. ANOVA (two-way) with Bonferroni’s post hoc test: ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001,
CT versus HF; 𝛿𝛿𝑝 < 0.01; 𝛿𝛿𝛿𝑝 < 0.001, HFT versus HF; #𝑝 < 0.05; ##𝑝 < 0.01; ###𝑝 < 0.001, HFA versus HF. Each bar graph represents the
mean ± SEM. ANOVA (one-way) with Bonferroni’s post hoc test: ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001, CT versus HF; 𝛿𝑝 < 0.05; 𝛿𝛿𝛿𝑝 < 0.001,
HFT versus HF; #𝑝 < 0.05, HFA versus HF (𝑛 = 5-6).
Histological assessment from HF-Y and HF-O liver
samples presented a pattern of NAFLD, characterized by
fatty infiltration (Figures 4(k) and 4(l)). Furthermore, HFD
groups (HF-Y and HF-O) showed hepatocellular disorga-
nization and inflammatory zones. Qualitatively, the groups
that received tempol (HFT-Y andHFT-O) showed a decrease
in hepatic fat accumulation, specifically in macro vesicular
steatosis, compared to the respective HFD group. A similar
condition was observed for the groups treated with apocynin
(HFA-Y and HFA-O) (Figures 4(k) and 4(l)).
The evaluation of the hepatic redox state was based on
the quantification of malondialdehyde as a lipid peroxidation
measure (Figures 5(a) and 5(b)), as well as the activities of
SOD (Figures 5(c) and 5(d)) and CAT (Figures 5(e) and 5(f))
in liver homogenates. Consumption of HFD increased lipid
peroxidation, without changes in SOD and CAT activities
in liver samples from young (HF-Y) and old (HF-O) mice
compared to their respective controls (CT-Y and CT-O).
Furthermore, these parameters were not altered after the
treatment with tempol and apocynin for both young and old
mice.
4. Discussion
The major findings of this work are the markedly increased
weight gain in aged mice fed a HFD compared to younger
ones, as well as the observation that the concomitant intake
of HFD and the treatment with antioxidant agents, here
represented by apocynin and tempol, improve insulin sen-
sitivity and glucose tolerance in aged mice. Our work also
demonstrated that HFD intake induces metabolic alterations
similar to those observed in humans presenting with MetS
and that NAFLD associated with dietary changes indeed
constitute another risk factor for the MetS, the advanced age
being an important contributing factor for augmenting such
alterations, mainly obesity and hepatic fat deposition [3].
Aging is characterized by a decline in biological func-
tions, with direct influence of lifestyle [34–36]. The data
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versus HF (𝑛 = 5-6).
presented herein showed that HFD intake for 14 weeks did
not induce body weight gain in young mice (20–22 weeks
old at the end of the dietary intervention). Nevertheless, this
period was effective in inducing a significant increase in body
weight in aged animals. However, young animals presented
a greater loss of heart and liver tissue when ingesting HFD,
which could compensate the HFD-induced obesity expected
in this MetS model. Taken together, these data also evidence
that aging andHFD synergistically contribute to accentuating
the decline in body capacity to metabolize fat, leading to a
greater accumulation of visceral adiposity.
Despite the fact that the HFD-fed young mice did not
present significant increase in body weight, other metabolic
parameters were shown to be considerably augmented due
to the HFD consumption, similar to the observations for
the old ones, reflecting, in both groups, the onset of MetS
[37–39]. Among thesemetabolic alterations, increased fasting
glucose, impaired glucose tolerance, increased lipid profile in
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Figure 5:Markers of redox state in liver. Hepatic lipid peroxidation ([TBARS] nM⋅mgprotein−1) in young (a) and old (b) C57BL/6mice. Total
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< 0.05; ∗∗𝑝 < 0.01, CT versus HF (𝑛 = 5-6).
plasma, and greater abdominal and hepatic fat deposition,
associated with increased AST and ALT plasma levels, could
be numbered. However, HFD-induced insulin resistance,
augmentation in TyG and HOMA indexes, and the increase
in plasma insulin concentration were only observed in aged
animals.
It is already known that the main contributing factor in
the aging process and the early development of metabolic
14 Oxidative Medicine and Cellular Longevity
diseases is represented by the oxidative stress [34], with the
latter enhancing the metabolic and vascular effects evoked
by HFD [39, 40]. In this sense, the referred couple of
factors, advanced age and dietary changes, might contribute
to increase the production of ROS which, in turn, directly
contribute to the onset and/or maintenance of glucose intol-
erance and insulin resistance [13, 41]. Notwithstanding, after
treatment with tempol and apocynin, concomitant with the
HFD intake, a significant improvement in these parameters
related to glucose metabolism was observed in aged mice,
in addition to the decrease in triglycerides and VLDL in
plasma. More interestingly, apocynin also decreased these
parameters in liver, corroborating the findings of improved
insulin sensitivity, as the augmented levels of these markers
in the liver are associated with insulin resistance. Together,
these data suggest that the increase in NAD(P)H oxidase
activity and the concentration of ∙O
2
− may be involved in the
mechanisms associated with the regulation of the glycemic
and lipid profile, with the presence of oxidative stress being
possible in this dietary model for MetS.
Tempol acts as a scavenger of ∙O
2
− [41, 42].Therefore, it is
plausible to assume that the use of this pharmacological agent
in the aged group in the current study may have contributed
to the reduction of ∙O
2
− and, thus, to the improvement in
glucose tolerance and insulin sensitivity. In accordance with
this statement, Banday and colleagues [41] found that tempol
ameliorates insulin sensitivity by promoting a reduction in
oxidative stress in obese Zucker rats, this way improving
insulin-mediated glucose uptake.
Apocynin, through its antioxidant action and/or its
inhibitory effect on the NAD(P)H oxidase enzymatic
complex, probably contributed to the observed metabolic
improvement at least partially by the reduced participation
of ROS [13, 20], ultimately suggesting that the increased
activity of the NAD(P)H oxidase enzymatic complex may
play an essential role in mechanisms related to the impaired
glycemic profile observed in the present work.
In line with these observations, Espinosa and colleagues
[16] showed that an increase in NAD(P)H oxidase 2 expres-
sion in skeletal muscle appears to be involved in the aug-
mented H
2
O
2
release upon insulin stimulation in insulin-
resistant mice [16]. Furthermore, the same study found that,
after treatment with apocynin for 8 weeks, HFD-fed mice
showed improved glucose tolerance and decreased fasting
insulin concentration. In addition, another experimental
work showed that the treatment with apocynin for 5 weeks in
HFD-fed mice was effective in improving glucose tolerance
and insulin sensitivity [9]. These studies, in part, corroborate
our findings concerning the antioxidant treatment and glu-
cose metabolism.
Advanced age also favored significant accumulation of
abdominal fat, a situation which implies a negative impact
on glycemic control [43]. Furthermore, the significant hepatic
fat deposition was more pronounced in aged animals, as
observed by the intense presence of micro and macro fat
vacuoles. Concerning this issue, the relation between age and
the degree of obesity and fat deposition was observed, due
to the consumption of HFD for 14 weeks. However, after
treatment with tempol and apocynin, the qualitative analysis
from liver histology showed a less accentuated presence of
fat vacuoles, quantitatively confirmed in HFA-O group by
a decrease in triglycerides and VLDL. Additionally, tempol
reduced the hepatic damage caused by HFD, as observed by
the reduction of AST and ALT, both markers of liver injury.
These data suggest that the antioxidant activity of apocynin
and the scavenger activity of tempol on ∙O
2
− seem to reduce
the hepatic oxidation of fatty acids during the chronic treat-
ment concomitant with the consumption of HFD, preventing
liver injury, and that the increased susceptibility of HFD-
induced MetS in old mice could be due to the increase of
redox imbalance during the aging process. Corroborating
the histological findings of the present work, several studies
showed the HFD-induced hepatic fat accumulation [3, 40].
Still, while assessing the liver histology, the presence of
inflammatory agglomerates suggests a direct participation of
hepatic fat accumulation in the elevated index of lipid perox-
idation observed in this organ, once the inflammatory milieu
evoked by fat deposition may contribute to augmenting the
local production of ROS. Taken together, these data suggest
thatHFD induced a state of steatohepatitis, a conditionwhich
characterizes the NAFLD [8], and that local oxidative stress
may be present and contribute in a direct manner to the
progression of NAFLD as well [6, 44]. Such occurrence could
be more likely due to the excessive production of ROS than
by a decrease and/or deficiency of antioxidant capacity, since
the activity of antioxidant enzymes SOD and CAT did not
significantly differ between HFD and chow diet groups.
The products generated in the process of lipid perox-
idation act as reactive agents, causing cell damage, which
amplifies the oxidative stress effects. Moreover, they induce
the production of inflammatory cytokines and subsequent
fibrosis, via activation of hepatic stellate cells [45]. Addition-
ally, there exists a correlation between plasma and hepatic
oxidative stress and clinical and histological findings in
patients presenting with NAFLD [44]. Accordingly, these
observations reassert the contribution of oxidative stress in
the progression of NAFLD in humans and, under this aspect,
our study points to the possible participation of the altered
oxidative state, arising from HFD consumption, in the onset
of steatohepatitis.
In this context, our results also indicate that the normal
hepatic redox state may be altered, possibly by an increase in
NAD(P)H oxidase activity and the elevated ∙O
2
− production.
Uchiyama and colleagues [46] suggest that oxidative stress
enhances hepatic fat deposition due to the degradation of
apolipoprotein B in the liver, indicating that such molecule
is a target for ROS. Reinforcing these observations, such
degradation process is caused by lipid peroxidation, as stated
in a study by Pan and colleagues [25].
In this sense, our data suggest that increased hepatic lipid
peroxidation in HFD animals may have directly contributed
to inhibiting hepatic release of VLDL to the systemic milieu.
In addition, different studies showed apocynin as an effective
pharmacological agent in ameliorating hyperlipidemia, hep-
atic steatosis [2], and insulin resistance [9], besides reducing
inflammatory factors such as leptin, interleukin-6, and TNF-
𝛼 [47], thereby indicating a protective role in diseases related
to the MetS and in the progression of NAFLD.
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Concerning the effects of apocynin on the oxidative state,
Meng and colleagues [9] showed that lipid peroxidation, both
hepatic and in plasma, was significantly reduced after an oral
treatment with such compound for 5 weeks. Furthermore,
the authors observed an increase in SOD activity and a
reduction in CAT activity in the liver, after treatment with
apocynin. Paradoxically, our findings differ in part from those
in the aforementioned study, since only in plasma, but not
in liver, the lipid peroxidation was decreased after apocynin
treatment in old mice. However, once the advanced age itself
represents a factor which culminates with the emergence of
redox imbalance [39], it is plausible to suggest that in the liver
the difference between treated and untreated groups with
antioxidant agents might have been masked by this factor.
In summary, our findings demonstrate that old mice
are more susceptible to HFD-induced metabolic changes
than young ones, with ROS generation presenting a close
relationship with the progression of NAFLD. Furthermore,
the improvement in glucose and lipid metabolism-related
parameters and the attenuation of the progression of NAFLD
in MetS mice, by using antioxidant agents, appears to be due
to the ability of these pharmacological agents to inhibit the
generation and accumulation of reactive species. Collectively,
our results point to the cross talk in the triad HFD-aging-
oxidative stress, once the HFD-induced metabolic derange-
ments may be more pronounced with the advance of age and
also potentially amenable to pharmacological interventions.
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